PE20191817A1 - Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) - Google Patents
Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)Info
- Publication number
- PE20191817A1 PE20191817A1 PE2019002310A PE2019002310A PE20191817A1 PE 20191817 A1 PE20191817 A1 PE 20191817A1 PE 2019002310 A PE2019002310 A PE 2019002310A PE 2019002310 A PE2019002310 A PE 2019002310A PE 20191817 A1 PE20191817 A1 PE 20191817A1
- Authority
- PE
- Peru
- Prior art keywords
- irak4
- interleukin
- inhibitors
- kinase
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Referido a un compuesto de formula I, en donde X es CR4 o N; Y es CR5 o N; o una sal o un profarmaco del mismo. Un compuesto preferido es 3-(((2S,3S)-3-etil-4,4-difluoro-5-oxopirrolidin-2-il)metoxi)-5-metoxitieno[3,2-b] piridin-6-carboxamida. Estos compuestos de tienopiridinas y benzotiofenos son inhibidores de cinasa 4 asociada al receptor de interleucina 1 (IRAK4). Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto su uso para tratar, prevenir o ralentizar enfermedades inflamatorias y autoinmunitarias, o para el tratamiento contra el cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504956P | 2017-05-11 | 2017-05-11 | |
| PCT/US2018/031945 WO2018209012A1 (en) | 2017-05-11 | 2018-05-10 | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191817A1 true PE20191817A1 (es) | 2019-12-27 |
Family
ID=62245511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002310A PE20191817A1 (es) | 2017-05-11 | 2018-05-10 | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10829496B2 (es) |
| EP (1) | EP3621960B1 (es) |
| JP (1) | JP7154229B2 (es) |
| KR (1) | KR102604900B1 (es) |
| CN (1) | CN110612298B (es) |
| AR (1) | AR111689A1 (es) |
| AU (1) | AU2018265130B2 (es) |
| BR (1) | BR112019023290A2 (es) |
| CA (1) | CA3062602A1 (es) |
| CL (1) | CL2019003198A1 (es) |
| CO (1) | CO2019012494A2 (es) |
| CY (1) | CY1124552T1 (es) |
| DK (1) | DK3621960T3 (es) |
| EA (1) | EA039189B1 (es) |
| ES (1) | ES2889926T3 (es) |
| HR (1) | HRP20211583T1 (es) |
| HU (1) | HUE056493T2 (es) |
| IL (1) | IL270494B (es) |
| LT (1) | LT3621960T (es) |
| MX (1) | MX2019012929A (es) |
| MY (1) | MY200228A (es) |
| PE (1) | PE20191817A1 (es) |
| PL (1) | PL3621960T3 (es) |
| PT (1) | PT3621960T (es) |
| RS (1) | RS62430B1 (es) |
| SI (1) | SI3621960T1 (es) |
| SM (1) | SMT202100568T1 (es) |
| TW (1) | TW201900640A (es) |
| WO (1) | WO2018209012A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES OF THE LATEST |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| CN114423757B (zh) | 2019-07-18 | 2024-07-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的三环杂芳基化合物 |
| WO2021011727A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS |
| KR20220041124A (ko) * | 2019-07-23 | 2022-03-31 | 브리스톨-마이어스 스큅 컴퍼니 | Irak4 억제제로서 유용한 티에노피리디닐 및 티아졸로피리디닐 화합물 |
| CN114174279B (zh) | 2019-08-06 | 2024-07-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的双环杂环化合物 |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4076520A4 (en) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| CN111285844B (zh) * | 2020-02-24 | 2022-08-12 | 河南师范大学 | 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| TW202241891A (zh) | 2020-12-30 | 2022-11-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
| JP2024506656A (ja) | 2021-02-15 | 2024-02-14 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその使用 |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| JP2025504059A (ja) | 2022-01-31 | 2025-02-06 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋデグレーダー及びその使用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8627698D0 (en) * | 1986-11-20 | 1986-12-17 | Boots Co Plc | Therapeutic agents |
| EP1399440B1 (en) | 2001-06-15 | 2009-06-03 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| AU2003244098A1 (en) | 2002-06-28 | 2004-01-19 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxa mide derivative |
| WO2004065378A1 (en) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| EP1651636A1 (en) | 2003-07-10 | 2006-05-03 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| US20060281778A1 (en) | 2005-03-09 | 2006-12-14 | Schering Corporation | Compounds for inhibiting KSP Kinesin activity |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| AR059246A1 (es) | 2006-01-30 | 2008-03-19 | Array Biopharma Inc | Compuestos heterobiciclicos de tiofeno y metodos de uso |
| CA2685588A1 (en) | 2007-06-08 | 2008-12-11 | Bayer Cropscience Sa | Fungicide heterocyclyl-pyrimidinyl-amino derivatives |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| JP5254693B2 (ja) | 2008-07-30 | 2013-08-07 | 三菱重工業株式会社 | Ｎｉ基合金用溶接材料 |
| JPWO2010058846A1 (ja) | 2008-11-21 | 2012-04-19 | アステラス製薬株式会社 | ４，６−ジアミノニコチンアミド化合物 |
| EA021367B1 (ru) | 2008-11-28 | 2015-06-30 | Кова Компани, Лтд. | Производное пиридин-3-карбоксамида |
| TW201100429A (en) | 2009-05-22 | 2011-01-01 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| IN2012DN02493A (es) | 2009-09-03 | 2015-08-28 | Allergan Inc | |
| BR112012010220A2 (pt) | 2009-10-30 | 2021-02-23 | Janssen Pharmaceutical N.V. | piridinas fenóxi-substituídas como modulares do receptor opioide |
| KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Ｇｐｒ119 작동약 |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| AU2012249240A1 (en) | 2011-04-29 | 2013-11-07 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitors |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| CN104159896B (zh) | 2012-01-13 | 2017-05-24 | 百时美施贵宝公司 | 用作激酶抑制剂的杂环取代的吡啶基化合物 |
| US8987311B2 (en) | 2012-01-13 | 2015-03-24 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| AU2013341185B2 (en) | 2012-11-08 | 2017-07-13 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses |
| US9546153B2 (en) | 2012-11-08 | 2017-01-17 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| WO2015150995A1 (en) | 2014-04-04 | 2015-10-08 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors |
| US10040802B2 (en) * | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of IRAK4 activity |
| EP3268367B8 (en) * | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamide inhibitors of irak4 activity |
| AR105114A1 (es) | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| CN107849039B (zh) | 2015-06-24 | 2020-07-03 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| PL3341367T3 (pl) | 2015-08-27 | 2021-07-12 | Pfizer Inc. | Skondensowane bicyklicznie związki heteroarylowe lub arylowe jako modulatory IRAK4 |
-
2018
- 2018-05-10 HR HRP20211583TT patent/HRP20211583T1/hr unknown
- 2018-05-10 ES ES18727589T patent/ES2889926T3/es active Active
- 2018-05-10 WO PCT/US2018/031945 patent/WO2018209012A1/en not_active Ceased
- 2018-05-10 PL PL18727589T patent/PL3621960T3/pl unknown
- 2018-05-10 LT LTEPPCT/US2018/031945T patent/LT3621960T/lt unknown
- 2018-05-10 BR BR112019023290-7A patent/BR112019023290A2/pt not_active Application Discontinuation
- 2018-05-10 CN CN201880031240.4A patent/CN110612298B/zh active Active
- 2018-05-10 AR ARP180101237A patent/AR111689A1/es unknown
- 2018-05-10 PT PT187275896T patent/PT3621960T/pt unknown
- 2018-05-10 RS RS20211247A patent/RS62430B1/sr unknown
- 2018-05-10 DK DK18727589.6T patent/DK3621960T3/da active
- 2018-05-10 EP EP18727589.6A patent/EP3621960B1/en active Active
- 2018-05-10 MX MX2019012929A patent/MX2019012929A/es unknown
- 2018-05-10 US US16/612,478 patent/US10829496B2/en active Active
- 2018-05-10 TW TW107115845A patent/TW201900640A/zh unknown
- 2018-05-10 AU AU2018265130A patent/AU2018265130B2/en not_active Expired - Fee Related
- 2018-05-10 JP JP2019561740A patent/JP7154229B2/ja active Active
- 2018-05-10 SI SI201830426T patent/SI3621960T1/sl unknown
- 2018-05-10 CA CA3062602A patent/CA3062602A1/en active Pending
- 2018-05-10 HU HUE18727589A patent/HUE056493T2/hu unknown
- 2018-05-10 SM SM20210568T patent/SMT202100568T1/it unknown
- 2018-05-10 EA EA201992674A patent/EA039189B1/ru unknown
- 2018-05-10 PE PE2019002310A patent/PE20191817A1/es unknown
- 2018-05-10 MY MYPI2019006520A patent/MY200228A/en unknown
- 2018-05-10 KR KR1020197036216A patent/KR102604900B1/ko active Active
-
2019
- 2019-11-07 IL IL270494A patent/IL270494B/en unknown
- 2019-11-07 CO CONC2019/0012494A patent/CO2019012494A2/es unknown
- 2019-11-07 CL CL2019003198A patent/CL2019003198A1/es unknown
-
2021
- 2021-10-07 CY CY20211100874T patent/CY1124552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191817A1 (es) | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) | |
| CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
| CO2020013865A2 (es) | Análogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| PE20151448A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PH12017501326A1 (en) | Tgf-� inhibitors | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| MX2018015892A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| PE20091720A1 (es) | Compuestos de benzopirano y benzoxepina como inhibidores de pi3k | |
| PE20151939A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| CR20110013A (es) | Derivados de Heteroarilo como Inhibidores de DGAT1 | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| ECSP11011258A (es) | Pirimidinas fusionadas | |
| NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| UY36708A (es) | MODULADORES DE ROR GAMMA (RORy) | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
| SA520412289B1 (ar) | مركبات مثبط الهدف الميكانيكي للراباميسين | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| PE20170294A1 (es) | Inhibidores de aldosterona sintasa | |
| BR112018010107A2 (pt) | composição farmacêutica para o tratamento ou prevenção de nash | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. |